arovella
THERAPEUTICS

ASX: ALA

Investor Presentation

Dr Michael Baker

February 2022

Disclaimer

1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Arovella Therapeutics Limited (**Company**).
In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.
2. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.
3. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.
4. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.
5. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.
6. This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction in which it would be unlawful. In particular, the New Shares and Options have not been, and will not be, registered under the US Securities Act of 1933 (the "US Securities Act") and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. The distribution of this presentation in jurisdictions outside Australia may be restricted by law and any such restrictions should be observed.
7. The New Shares and Options will be offered and sold in the United States only to (i) institutional accredited investors (as defined in Rule 501(a)(1), (2), (3) and (7) under the US Securities Act); and (ii)dealers or other professional fiduciaries organized or incorporated in the United States that are acting for a discretionary or similar account (other than an estate or trust) held for the benefit or account of persons that are not US persons and for which they exercise investment discretion, within the meaning of Rule 902(k)(2)(i) of Regulation S under the US Securities Act.

arovella THERAPEUTICS

Arovella Therapeutics Highlights

World Leading Partners

Arovella licenced its iNKT Cell Therapy Platform from Imperial College London and its DKK1 mAb/CAR from MD Anderson

Allogeneic Platform, Two Targets

Arovella is developing off the shelf cell therapies for CD19 expressing lymphomas and DKK1 producing cancers

Acquiring New Technologies

Arovella continues to focus on sourcing, evaluating and acquiring innovative technologies that align with key focus areas

World Class Team

Arovella's leadership group has deep experience in drug development, particularly cell therapies

Data Driven

Arovella uses data to drive decision making for its key assets and clinical indications

Growth Potential

Arovella is the only ASX listed company working with an iNKT cell therapy platform and the only company worldwide with CAR technology targeting a DKK1 peptide

arovella THERAPEUTICS

Recent Milestones



Arovella Company Overview

Financial Snapshot

ASX CODE	ALA
Market capitalisation[1]	$24 million
Enterprise value	$15 million
Shares on issue[1]	601 million
52-week low / high	$0.033 / $0.075
Cash (30 December 2021) [2]	$8.8 million

Major Shareholders

Shareholder	Ownership (%)[1]
MERCHANT FUNDS MANAGEMENT PTY LTD	47,416,660 (7.89%)
MANN BEEF PTY LTD	20,000,00 (3.33%)
UBS NOMINEES PTY LTD	15,064,640 (2.51%)
ZERRIN INVESTMENTS PTY LTD	14,625,227 (2.43%)
DYLIDE PTY LTD	12,500,000 (2.08%)

1. *As of 31 January 2022 and including shares issued from the Placement announced 24 January 2022*
2. *Includes the proceeds from the Placement but not the $1.5m from the underwritten SPP announced 24 January 2022*

Arovella Board and Senior Leadership

Paul Hopper

CHAIRMAN

Over 25 years experience in the medical, healthcare & life sciences sectors. Focussed on start-up and rapid growth companies, he has served as either Founder, Chairman, non-executive director or CEO, of more than fifteen companies in the US, Australia and Asia. Mr Hopper has founded, or technology seeded, six companies on the ASX and Nasdaq.

Dr. Michael Baker

CEO & MANAGING DIRECTOR

Over 15 years experience in scientific research, drug development and venture investing sectors. He was an Investment Manager with the leading Australian life science fund, BioScience Managers. He also conducted due diligence to shortlist investment opportunities and played an active role in managing portfolio companies.

Dr. Debora Barton

DIRECTOR

Over 20 years of oncology experience, in academia, as a practicing physician and in the biotechnology / pharmaceutical industry. Served in key senior executive positions, including Carisma Therapeutics where Dr. Barton is currently the Chief Medical Officer, Iovance Biotherapeutics and Advanced Accelerator Applications, acquired by Novartis during Debora's tenure.

Dr. Liz Stoner

DIRECTOR

Dr. Stoner is a distinguished biopharma executive, who brings decades of international industry experience to her role, including senior roles in Clinical Development Operations at Merck Research Laboratories. Liz is an Executive Partner at MPM Capital, and she has held numerous leadership roles at MPM portfolio companies. Liz was previously an Assistant Professor of Paediatrics at Cornell University Medical College.

Dr. Sandhya Buchanan

VP MANUFACTURING & QUALITY

Dr Buchanan has more than 20 years' experience working in cell & gene therapy and vaccine development. Dr Buchanan was formerly at Atara Biotherapeutics as the chemistry manufacturing and control technical lead for autologous CAR-T programs and head of Viral Vector Development. Dr Buchanan has a PhD in Pharmaceutical Sciences from the University of Colorado Health Sciences Center

David Simmonds

DIRECTOR

David was a senior audit partner with Ernst & Young from 1989 to 2017. From 2008 to 2013, David led the Capital Markets desk in Australia with responsibility for overseeing or reviewing all Australian cross border fundraisings. David was a member of the Board of MS Research Australia.

arovella THERAPEUTICS

Arovella Therapeutics Pipeline

Cell Therapy

	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1	PHASE2/3[1]	PARTNER
ALA-101 (CAR19-iNKT)	**CD19 expressing cancers**	CD19 Expressing Lymphoma				
ALA-102	**Not Disclosed**	ND				
ALA-103	**Not disclosed**	ND				
ALA-104 (DKK1-CAR-iNKT)	**Multiple Myeloma**	Multiple Myeloma & Solid Tumours				

OroMist

	INDICATION	REFORMULATION	PRECLINICAL	CLINICAL	COMMERCIAL	PARTNER
ZolpiMist®[2]	**Short-term insomnia**	Short-term insomnia				Teva[3] STADA[4]
ALA-001 (Sumatriptan)	**Migraine**	Migraine				Strides
ALA-018 (Anagrelide)	**Solid tumours & thrombocytosis**	Solid Tumours				
ALA-021 (Pharma grade Cannabis)	**DRE[5], melanoma, motion sickness**	Multiple				Cann Pharma Australia
ALA-023 (Not disclosed)	**Not Disclosed**	ND				Sanofi

1. *Phase 3 trial may not be required if Phase 2 is a registrational trial*
2. *ZolpiMist has been approved by the Ministry of Health (Chile), TGA (Australia) and the FDA (US) and Arovella holds the rights to ZolpiMist outside of North America*
3. *Arovella is assisting TEVA with regulatory submission and commercialisation efforts*
4. *STADA have the license to commercialise ZolpiMist in Australia*
5. *DRE – Drug Resistant Epilepsy*

Cell Therapy Commercial Activity

Transactions		
Parties	**Deal Type**	**Total Value**
Gilead / Kite	Acquisition	**US$11.9b**
Celgene / Juno	Acquisition	**US$9b**
Janssen / Fate	Partnership	**US$3b**
Kite / Shoreline Biosciences	Strategic Partnership	**US$2.3b**
Atara Bio / Bayer	Strategic Collaboration	**~US$670m**
Gilead / Cell Design Labs	Acquisition	**US$567m**
Caribou / Abbvie	Collaboration Agreement	**US$340m**
Moderna / Carisma Therapeutics	Research Deal	**US$45m**[1]

Significant Capital Raises	
Company	**Amount Raised**
Sana Biotech	**US$675m**
Lyell	**US$425m**
Legend Biotech	**US$424m**
Carsgen	**US$400m**
Instil Bio	**US$368m**
Century Therapeutics	**US$243m**
Gracell	**US$209m**

- The global cell and gene therapy market is expected to reach US$12.9b by 2026[2]

1. *Milestone payments are included but have not been disclosed*
2. *https://www.globenewswire.com/news-release/2021/12/08/2348195/0/en/Global-Gene-and-Cell-Therapy-Market-Size-Points-22-3-CAGR-Projected-to-Reach-USD-12-9-Billion-by-2026-Facts-Factors.html*

arovella THERAPEUTICS

Commercial Activity for iNKT Cell Therapies

Value

APPIA BIO	kuur THERAPEUTICS	MiNK Therapeutics	arovella THERAPEUTICS
Strategic Partnership US$875m Total[1] Preclinical	**Acquisition US$185m Total[3] Phase 1**	**Market Cap US$110m[2] Phase 1**	**Market Cap AU$24m[2,4] Preclinical**
May 2021 – Appia Bio raised US$52m in their Series A **Aug 2021 –** Appia Bio entered into Strategic Partnership with Kite Pharma - US$875m deal value	**May 2021 –** Kuur Therapeutics was acquired by Athenex for US$70m upfront and US$115m milestone payments	**Oct 2021 –** MiNK Therapeutics listed on the Nasdaq raising US$40m, currently valued at US$110m[1]	**Jun 2021 –** Acquired the licence to its iNKT cell therapy platform from Imperial College London **Dec 2021 –** Acquired the licence to the DKK1 technology from MD Anderson Cancer Center **Jan 2022 -** Placement and SPP

1. https://www.gilead.com/news-and-press/press-room/press-releases/2021/8/kite-and-appia-bio-announce-collaboration-to-research-and-develop-allogeneic-cell-therapies-for-cancer
2. *As of 31 January 2022*
3. *https://ir.athenex.com/news-releases/news-release-details/athenex-acquire-kuur-therapeutics-expand-cell-therapy*
4. *Including shares issued from the Placement announced 24 January 2022*

arovella THERAPEUTICS

iNKT Cell Therapy Platform

Imperial College London

arovella THERAPEUTICS

Overview of CAR-iNKT Cell Therapy

Blood Collection and Immune Cell Harvesting

- Following blood collection from a healthy donor at a hospital or clinic, immune cells are collected

Isolation and re-programming of immune cells

- Isolated iNKT cells are genetically re-programmed to produce a chimeric antigen receptor (CAR) that will attack specific markers on cancers

Multiplication of cells

- The CAR-iNKT cells are grown up to sufficient numbers for patient treatment and stored frozen

Cells are administered to the patient

- When CAR-iNKT cells are required, they are thawed and administered, and they will find and kill the cancer cells



Expand the Cell Therapy Revolution: iNKT Cells



iNKT Cell Benefits

- They are one of the most potent, naturally occurring immune cells
- They bridge the innate and adaptive immune system
- They naturally target and kill cancer cells
- They activate other beneficial immune cells
- They can be used “off the shelf” as they suppress graft versus host disease (GVHD)
- They show significantly improved killing of CD1d producing cancers over T cells when combined with chimeric antigen receptors (CARs)

arovella THERAPEUTICS

CAR-iNKT Cells are Engineered to Enhance Activity

	APPROVED CAR-T CELLS	CAR-NK CELLS	CAR-iNKT CELLS
Subpopulation of T cells with NK cell properties	✗	✗	✓
Intrinsic anti-cancer receptor (dual targeting)	✗	✗	✓
Persistence	✓	TBD	TBD[1]
Minimal genetic engineering for off the shelf	✗	✓	✓
Naturally suppress GVHD	✗	✗	✓
Low risk of CRS or neurotoxicity	✗	✓	✓
Allogeneic, 'off-the-shelf' dosing	✗	✓	✓

CAR – Chimeric Antigen Receptor; iNKT – invariant Natural Killer T Cell; CRS – Cytokine Release Syndrome; TBD – To Be Determined

1. Spontaneous secondary remission observed in preclinical animal models

arovella THERAPEUTICS

How does the CAR-iNKT Cell Therapy Platform Work?

1. iNKT cells contain an iTCR that naturally assists to recognise and kill cancer cells that have CD1d on their surface
2. We introduce a chimeric antigen receptor (CAR) to target cancer cells, making them dual targeting
3. CAR-iNKT cells are activated after they attach to the cancer cells, releasing components to trigger cancer cell death
4. The cancer cell is killed, and other components are recruited to assist



arovella THERAPEUTICS

ALA-101: CAR19-iNKT Cells to Treat Blood Cancers

- ALA-101 is anticipated to be an effective, off-the-shelf cell therapy for the treatment of CD19 expressing cancers
- We have demonstrated robust activity against CD19 expressing cancers
- ALA-101 is more efficient at clearing tumour cells than conventional cell therapies when the cancers produce CD1d
- Our therapy results in better animal survival than conventional cell therapies
- Our data validates the use of iNKT cells as a treatment for CD19 expressing cancer types
- We commenced the manufacturing of the plasmid and lentivirus in Q1 2022

CAR19-iNKT Outperforms Conventional Therapies

Faster Killing of Cancer Cells That Have CD1d



Spontaneous Secondary Remission



Increased Survival Over CAR-T Cells



Rotolo *et al.*, Cancer Cell (2018)

Pipeline Expansion
ALA-104

arovella
THERAPEUTICS

Development of DKK1-CAR to Date

- The DKK1 mAb was developed at MD Anderson and can be incorporated into a chimeric antigen receptor (CAR)
- The DKK1 peptide-targeting mAb has demonstrated activity against multiple myeloma and breast cancer
- The DKK1 peptide-targeting scFv has been incorporated into CAR-T cells, and has excellent activity against blood cancers and solid tumours (unpublished data)
- Arovella will combine the DKK1-CAR with its iNKT cell therapy platform and initially target multiple myeloma, where DKK1 is highly expressed

Already Completed



DKK1-CAR-T cells

Multiple Myeloma ✓
Pancreatic Cancer ✓
Lung Cancer ✓
Breast Cancer ✓

Arovella To Complete



DKK1-CAR-iNKT cells

Multiple Myeloma
Pancreatic Cancer
Lung Cancer
Breast Cancer

DKK1-CAR-T Cell Activity in Multiple Myeloma

DKK1-CAR T cells were tested in three different animal models for multiple myeloma, displaying robust activity in all standard models







- All treated mice were alive at 50-60 days, while untreated mice succumbed to the cancer at 30-40 days
- Multiple myeloma cells also express CD1d, so including DKK1-CAR into iNKT cells will make them dual targeting
- DKK1-CAR-T cells also have activity in animal models for **lung**, **pancreatic** and **triple negative breast** cancer

DKK1-CAR-T Preclinical Safety

Prof Qing Yi at Houston Methodist has demonstrated:

- They only kill cells that have the DKK1 peptide presented in an HLA-A2 complex on their surface
- They do not kill healthy blood cells
- That the DKK1-CAR-T cells are considered safe using *in vivo* models
- The DKK1 mAb targeted only 1 out of 35 normal tissues tested (tonsil)

Arovella will confirm:

- That the DKK1 technology does not target or attack healthy cells
- The ability to combine DKK1-CAR with Arovella's iNKT cell therapy platform

arovella THERAPEUTICS

The Inventor – Professor Qing Yi

Professor Qing Yi is a trained medical immunologist with over 25 years of experience. He is one of the leading investigators in the fields of tumor immunology and immunotherapy in multiple myeloma and other cancers. He has trained at the **Karolinska Institute**, **MD Anderson**, the **Cleveland Clinic** and is now at **Houston Methodist**.

Professor Yi is the Director for the Center for Translational Research in Hematological Malignancies and Associate Director for the Cancer Center Basic Research Programs, Cancer Center Houston Methodist.

Professor Yi has been awarded 9 R01 grants, 1 project and 1 core grant in the MD Anderson Myeloma SPORE (P50), 4 R01-type translational grants from the LLS, 4 Senior Researcher Awards from the MMRF, 2 K99/R00 grants, and numerous intramural and industry grants. Dr Yi was recruited to Houston Methodist through an Established Investigator Award from CPRIT with a total grant amount of ~$6 million.

Professor Yi and colleagues have published more than 160 peer-reviewed research articles, with 45 being in top-tier journals with an impact factor of greater than 10.

DKK1's Role in Cancer

2021

Oncogene,
2021 Jul 01; 40(26)

The dickkopf1 and FOXM1 positive feedback loop promotes tumor growth in Pancreatic and Esophageal Cancers

2019

Annals of translational medicine,
2019 Dec 21; 146(2)

Crosstalk of estrogen receptors and wnt/β-catenin signaling in Endometrial Cancer

2019



Oncogene,
2019 Dec 06; 38

Dickkopf-1 contributes to Hepatocellular Carcinoma tumorigenesis by activating the Wnt/β-catenin signaling pathway

2019

American journal of cancer research,
2019 Feb 01; 9(2)

Dickkopf-1 (DKK1) promotes tumor growth via akt-phosphorylation and independently of wnt-axis in barrett's associated Esophageal Adenocarcinoma

2018



Clinical & experimental medicine,
2018 Sep 2035(8)

Dickkopf-1 (Dkk1) protein expression in Breast Cancer with special reference to Bone Metastases

2018



Oncogene,
2018 Mar 18; 37(26)

Activation of the dickkopf1-CKAP4 pathway is associated with poor prognosis of Esophageal Cancer and anti-CKAP4 antibody may be a new therapeutic drug

2017

Cell cycle,
2017 Jul 27; 16(17)

The role of dickkopf-1 as a potential prognostic marker in Pancreatic ductal adenocarcinoma

2016



Oncotarget,
2016 Sep 06; 7(43)

Dickkopf-1 expression is associated with tumorigenity and lymphatic metastasis in human hilar Cholangiocarcinoma

2016

Journal of cellular and molecular medicine,
2016 May 31; 20(9)

Dickkopf-1-promoted vasculogenic mimicry in Non-small Cell Lung Cancer is associated with EMT and development of a cancer stem-like cell phenotype

2015



Oncotarget,
2015 Jun 19; 6(23)

Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of Pancreatic Cancer

- DKK1 is overproduced in a number of cancer types, including pancreatic, oesophageal, hepatocellular, breast, lung cancer and multiple myeloma
- Overexpression of DKK1 can indicate poor overall survival and shorter disease-free survival[1]
- DKK1 has recently emerged as a potential biomarker of cancer progression and prognosis for several types of malignancies[2]
- There is growing evidence that DKK1 plays an essential role in cancer progression[2]

1. Zhu et al., 2021

2. Chu et al., 2021

arovella THERAPEUTICS

Robust Intellectual Property

- **Patent life until 2039**
- As the first DKK1-CAR product, it has a robust patent position
- Title: Monoclonal Antibodies Against MHC-Bound Human Dickkopf-1 Peptides and Uses Thereof
- Applicant: Board of Regents, The University of Texas System
- Patent applications have been filed in the US, Europe, Canada, China, and Australia
- Favorable Search Report

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 August 2020 (06.08.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/160532 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 35/00* (2006.01)
C07K 16/28 (2006.01) *C07K 14/705* (2006.01)

(21) International Application Number:
PCT/US2020/0 16364

(22) International Filing Date:
03 February 2020 (03.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/800,007 01 February 2019 (01.02.2019) US

(71) Applicant: **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 210 West 7th St., Austin, TX 78701 (US).

(72) Inventors: **YL, Qing;** C/o The University Of Texas Md Anderson, Cancer Center, 1515 Flolcombe Blvd., Houston, TX 77030 (US). **QIAN, Jianfei;** C/o The University Of Texas MD Anderson, Cancer Center, 1515 Flolcombe Blvd., Houston, TX 77030 (US).

(74) Agent: **SCHNEPP, Amanda, S. J.;** Parker Highlander PLLC, 1120 So. Capital Of Texas Highway, Bldg. One, Suite 200, Austin, TX 78746 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

arovella THERAPEUTICS

CAR-iNKT Cell Therapy Development

- Acquire the license to additional CARs/Technologies complementary to the iNKT cell therapy platform
- Dose first patient in Phase 1 clinical trial for CD19 producing cancers
- FDA IND clearance for CAR19-iNKT program
- Complete GMP manufacturing of CAR19-iNKT cells for phase 1 clinical trial
- Define Manufacturing strategy for DKK1-CAR-iNKT cells
- Demonstrate activity of DKK1-CAR-iNKT cells in models for multiple myeloma, and potentially solid tumours
- Confirm Safety and Specificity of the DKK1-CAR and combine with the iNKT cell platform
- Select GMP manufacturer to produce CAR19-iNKT cells
- Recruit cell therapy translation and development expert ✓
- Select GMP manufacturer for plasmid and lentivirus for CAR19 ✓
- Acquire the license to another complementary CAR ✓
- Recruit cell therapy manufacturing expert – Dr. Sandhya Buchanan ✓
- Enter into Research Agreement with Imperial College London ✓

arovella THERAPEUTICS

CAR-iNKT Cell Manufacturing Pathway

Key Components

- Plasmid DNA encoding the CAR
- Lentiviral vector to deliver the CAR
- iNKT cells to produce the CAR (final product)

Prepare plasmid and Lentiviral vector for the CAR

Use the GMP Lentiviral Vector to prepare CAR-iNKT cells[1]



1. *Does not depict the development work for the CAR-iNKT cells, which will be performed in parallel*

Thank You

Dr Michael Baker
CEO & Managing Director

Email: mbaker@arovella.com
Mobile: +61 403 468 187

arovella
THERAPEUTICS

Appendices

Cancer Continues to be a Major Health Issue

Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer)) occurred in 2020[1]

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020[2]

The global cancer biologics market should reach $143.0 billion by 2026 from $77.5 billion in 2021 at a (CAGR) of 13.0%[3]

1. https://pubmed.ncbi.nlm.nih.gov/33538338/
2. https://www.who.int/news-room/fact-sheets/detail/cancer
3. https://www.businesswire.com/news/home/20211004005398/en/Global-Market-for-Biological-Therapies-for-Cancer-2021-2026---ResearchAndMarkets.com

arovella THERAPEUTICS

Chimeric Antigen Receptor (CAR) Cell Therapy Revolution

CAR-T Revolution

Due to their impressive cure rates, CAR-T cell therapies have revolutionised the treatment of cancer. As of October 2021, there are five approved CAR-T products to treat a number of haematological malignancies



Product	Approval Year	2020 Revenue
KYMRIAH® (tisagenlecleucel) Suspension for IV infusion	2017	US$474m[1]
YESCARTA® (axicabtagene ciloleucel) Suspension for IV infusion	2017	US$563m[2]
TECARTUS™ (brexucabtagene autoleucel) Suspension for IV infusion	2020	US$44m[2]
Breyanzi® (lisocabtagene maraleucel) SUSPENSION FOR IV INFUSION	2021	NA
Abecma™ (idecabtagene vicleucel) SUSPENSION FOR IV INFUSION	2021	NA

1. https://www.businesswire.com/news/home/20210204006011/en/Gilead-Sciences-Announces-Fourth-Quarter-and-Full-Year-2020-Financial-Results
2. https://www.novartis.com/sites/www.novartis.com/files/q4-2020-investor-presentation.pdf

arovella THERAPEUTICS

What are Chimeric Antigen Receptors (CARs)?

Immune Cell

CD19-CAR



CAR-Producing Cell



Cancer Cell



Specific immune cells for the therapy are collected from a patient or a healthy volunteer

The immune cells are genetically re-programmed with a CAR, supercharging them to seek out and destroy specific cancer cells

Once administered to the cancer patient, the CAR-producing cells can seek out and destroy the cancer cells

arovella THERAPEUTICS

Preclinical *In Vivo* Safety Evaluation of CAR19-iNKT cells

CAR19-iNKT cells do not elicit adverse effects in preclinical mouse tumour models

- No body weight loss
- Data in mouse models did not show off-target effects
- No histological changes in normal tissues
- Beside the profound anti-lymphoma effect of CAR19-iNKT cells, there was no evidence of negative pathology findings, clinically or as determined by extensive histopathological analysis

Mice Body Weight



Rotolo *et al.*, Cancer Cell (2018)

arovella THERAPEUTICS

iNKT Cells Protect Against Graft Versus Host Disease

2017



Front Immunol
2017 July 31;8:900
Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation

2017

Leukemia
2017 Apr;31(4):903-912
Pre-transplant donor CD4⁻ invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease

2016



Blood
2016 Apr 7;127(14):1828-35
Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival

2015



Blood
2015 May 28;125(22):3374-3375
A party of three: iNKT cells in GVHD prevention

2015



Blood
2015 May 28;125(22):3491-3500
Third-party CD4⁺ invariant natural killer T cells protect from murine GVHD lethality

2014

Blood
2014 Nov 20;124(22):3320-3328
CD4⁺ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4⁺CD25⁺FoxP3⁺ regulatory T cells

2012

Blood
2012 May 24;119(21):5030-6
Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation

2011

Blood
2011 Mar 17;117(11):3220-3229
Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4–dependent mechanism

2010

Transfusion
2010 Feb;50(2):407-17
Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation

2008

J Immunol.
2008 Sep 1;181(5):3268-76
Human Invariant NKT Cells Display Alloreactivity Instructed by Invariant TCR-CD1d Interaction and Killer Ig Receptors

- Conventional CAR-T cell therapies are limited to autologous products due to the potential for acute graft versus host disease (GVHD)
- Allogeneic CAR-T cell products require additional genetic engineering
- Invariant Natural Killer T (iNKT) cells have been shown to intrinsically protect against GVHD
- Arovella's CAR-iNKT cell therapies will be developed as allogeneic products, requiring minimal genetic engineering

arovella THERAPEUTICS

Use of iNKT Cells in Clinical Trials

2020

[Nat Med](#)
2020 Nov;26(11):1686-1690.
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis

2017



[Clin Cancer Res](#).
2017 Jul 15;23(14):3510-3519
Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial

2013

[Blood](#)
2013 Jan 17;121(3):423-430
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma

2012



[J Clin Immunol.](#)
2012 Apr 26;32(5):1071-81
Accumulation of Activated Invariant Natural Killer T Cells in the tumour Microenvironment after α-Galactosylceramide-Pulsed Antigen Presenting Cells

2011

[Clin Cancer Res.](#)
2011 Aug 1; 17(15):5140-51
Comparison of Clinical and Immunological Effects of Intravenous and Intradermal Administration of α-GalactosylCeramide (KRN7000)-Pulsed Dendritic Cells

2009

[J Immunol.](#)
2009 Feb 15;182(4):2492-501
A Phase I-II Study of α-Galactosylceramide-Pulsed IL-2/GM-CSF-Cultured PBMCs in Patients with Advanced and Recurrent NSCLC

2008

[Cancer Immunol Immunother.](#)
2008 Mar;57(3):337-45
Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent HNC

2006

[Clin Cancer Res](#).
2006 Oct 15;12(20 Pt 1):6079-86
A Phase I Study of *In vitro* Expanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer

2005

[J Exp Med.](#)
2005 May 2;201(9):1503-17
Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients

2005

[Clin Cancer Res](#).
2005 Mar 1;11(5):1910-17
A Phase I Study of α-Galactosylceramide (KRN7000)–Pulsed Dendritic Cells in Patients with Advanced and Recurrent NSCLC

- iNKT cells, in the presence and absence of CARs, have been used in numerous clinical trials against a range of tumour types, including blood cancers and solid tumours
- Efficacy data is encouraging in both solid tumour and haematological malignancies
- The side effect profile is encouraging with low risk of neurotoxicity and cytokine release syndrome with no evidence of GVHD for allogeneic iNKT cell products

arovella THERAPEUTICS

A Novel Cancer Target – DKK1 (ALA-104)

- DKK1 is a secreted protein that functions as a negative regulator of the Wnt signaling pathway
- DKK1 is overproduced in numerous cancer types and DKK1 peptides are loaded onto immune complexes and presented at the surface of cancer cells
- Our DKK1 mAb/CAR targets a specific DKK1 peptide in an HLA-A2 complex
- ~40-50% of the population is HLA-A2 +ve meaning the market for the DKK1-CAR could be quite large



Understanding Immunology and Cell Therapy

- **Antigen =** Any substance that induces the immune system to produce antibodies against it is called an antigen. Any foreign invaders, such as pathogens (bacteria and viruses), chemicals, toxins, and pollens, can be antigens.
- **CAR** = Chimeric Antigen Receptor can be introduced into immune cells to target cancer cells.
- **CAR-T** = Chimeric Antigen Receptor T Cell.
- **iNKT** = invariant Natural Killer T cells are components of the immune system that seek and destroy foreign or abnormal cells.
- **TCR** = T Cell Receptors are group of proteins found on immune cells that recognise fragments of antigens as peptides bound to MHC complexes.
- **CD1d** = Cluster of differentiation 1, which is expressed on some immune cells and cancer cells.
- **CD19 =** Cluster of Differentiation 19 is a protein that is expressed in a B cells and many cancer cell types.
- **Cell Therapy =** The use of intact cells to lessen or cure a disease. Cells may be from the patient (autologous) or from a healthy donor (allogenic).
- **Immuno-oncology** = The use of the immune system to treat cancer.
- **Invariant =** Never changing.
- **In vitro =** Work completed in a test tube or outside of an animal.
- **In vivo =** work completed using an organism (i.e. mouse, human).
- **Lymphomas =** Lymphoma is a cancer of the lymphatic system, which is part of the body's germ-fighting network.
- **Novel =** Of new or unusual kind.
- **Platform =** A systematic method to leverage prior knowledge for a given new therapy.

arovella THERAPEUTICS

arovella THERAPEUTICS

Committed to helping people live longer and healthier lives

Patient-Centric
It starts with the end in mind. In our case, it is our patients.
At Arovella, we are invested in making a positive difference in helping patients live longer and healthier lives. Creating a brighter future for people is our driving force.

Data-driven and Milestone Focused
Behind all life-changing therapies is excellent, ground-breaking science. We utilise data to shape our decisions to enable us to reach our set milestones

Accountable, Honest and We Act With Integrity
Our mission of helping patients focuses us. We hold ourselves to account for our actions. We strive to do what is right for all of our stakeholders.

We Are Persistent and Never Give Up
Drug development is a challenging arena. We are committed to our mission of helping patients, and we will continue to push each other through positive and challenging times in the pursuit of developing life-changing therapeutics.